IPA Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and Licensing Agreement to Discover and Develop Antibodies Against Cancer

VICTORIA, British Columbia and VANCOUVER, British Columbia and PHILADELPHIA, November 30, 2022–(BUSINESSWIRE)–IPA (IMMUNOPRECISE ANTIBODIES LTD.) (“IPA”) (NASDAQ: IPA), a leading biotherapeutic research and technology company, today announces that BioStrand BV (“BioStrand”), a subsidiary of IPA specializing in in the discovery in silico Powered by AI, has signed a Research Collaboration and Licensing Agreement (the “Agreement”) with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company specializing in targeted cancer immunotherapies.

This press release contains multimedia elements. See the full press release here: https://www.businesswire.com/news/home/20221130005424/en/

The collaboration will be based on BioStrand’s LENSai™ software, built on IPA’s proprietary HYFT™ Universal Fingerprint™ technologies, and will focus on the discovery in silico of antibodies to generate clinically relevant molecules for potential development. Under the terms of the Agreement, BioStrand and BriaCell will collaborate on the design, discovery and development of anti-cancer antibodies. Once antibodies are discovered, BioStrand will receive an upfront payment of $500,000, and will be eligible to receive future milestone payments for successful developments, including New Drug Application (NDA) submission, clinical milestones, and commercial royalties on net product sales. Other terms are not disclosed.

“We are excited to begin this program with BriaCell and apply our technology to the development of biological agents that could have significant clinical impact,” said Dr. Ingrid Brands, CEO and co-founder of BioStrand. “Shortening timelines, while integrating as much information as possible upstream to improve process efficiency, are extremely important aspects in the development of highly targeted therapies. It is also a step forward in realizing our long-term vision of promoting precision medicine. »

“We believe that BioStrand’s AI-powered technology, combined with its state-of-the-art protein engineering platform, will enable us to design and discover potent cancer therapeutics,” said Miguel A. Lopez-Lago, PhD, Chief Scientific Officer by BriaCell. “This approach would complement BriaCell’s portfolio of innovative cancer immunotherapies. »

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at www. BriaCell.com

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe, including entities such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) BV (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling and complex artificial intelligence systems to support its proprietary antibody discovery technologies based on a bioplatform. These services include the discovery, development and out-licensing of highly specialized and comprehensive therapeutic biologics, supporting its commercial partners seeking to discover and develop new biologics to combat the most complex targets. For more information, please visit our website www.ipatherapeutics.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identifiable by the use of words such as “potential”, “plans”, “hopes” or “does not hope”, “should”, “estimates”, “intends”, “anticipates or “does not anticipate”, or “believe”, or the use of other words and expressions or which indicate that certain measures, certain events or certain results “may”, “could”, “would”, “could”. maybe” or “will” be taken, take place, or are achieved. Forward-looking information in this press release includes, but is not limited to, statements relating to the impact and anticipated results of IPA’s collaboration with BriaCell as well as statements relating to the amount and timing of payments and royalties. that BriaCell will receive. With respect to the forward-looking information contained herein, IPA has provided such statements and information based on certain assumptions that management believed to be reasonable at the time.

Forward-looking information involves known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the results of IPA’s collaboration with BriaCell may not be as beneficial as it expected, milestones leading to payments from BriaCell may not be (all) achieved, the amount of worldwide net sales leading to commercial royalties may be lower than expected; as well as the risks listed in the Company’s Annual Information Form dated July 28, 2022 (which can be viewed on the Company’s profile at www.sedar.com) and on the company’s Form 40-F, dated July 29, 2022 (which can be viewed on the Company’s profile at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this Press release. Readers are therefore cautioned not to place undue reliance on the forward-looking information contained in this press release. The forward-looking statements contained in this press release are made as of the date of this press release and, accordingly, are subject to change after such date. The Company undertakes no obligation to update or revise any forward-looking statements, whether written or oral, that we may make or that may be made by us, except as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20221130005424/en/

contacts

(ImmunoPrecise Antibodies Ltd.):

Investors: investors@ipatherapeutics.com

(BriaCell Therapeutics Corp.):

William V. Williams, MD
President and CEO
1-888-485-6340
info@briacell.com

Media Relations:
Jules Abraham
Public Relations Director
COREIR
917-885-7378
julesa@coreir.com

Investor Relations:
COREIR
investors@briacell.com

We would like to thank the writer of this write-up for this awesome content

IPA Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and Licensing Agreement to Discover and Develop Antibodies Against Cancer


Visit our social media profiles as well as other related pageshttps://www.ai-magazine.com/related-pages/